[{"from": "human", "value": "Provide a brief overview of this molecule. [C][Branch1][#Branch2][C@@H1][Branch1][=Branch1][C][=Branch1][C][=O][O][N][S][C][C][=Branch1][C][=O][O]"}, {"from": "gpt", "value": "The molecule are common symptoms of chronic obstructive pulmonary disease (COPD) and other respiratory conditions characterized by increased mucus production. Individuals with COPD have a greater risk of pulmonary infection due to the growth and accumulation of viruses and bacteria in thick bronchial mucus. Carbocisteine is a mucolytic drug that alleviates respiratory symptoms and infections by reducing the viscosity of mucus, allowing it to be expelled.  Several licenses for this drug were withdrawn following serious and fatal paradoxical effects after carbocisteine therapy in children; respiratory dress, dyspnea, and cough aggravation were reported by physicians in France and Italy.  Carbocisteine is currently not FDA or Health Canada approved, but is approved for use in Asia, Europe, and South America."}]